Targeted therapy and chemo for HER2-positive breast cancer before surgery
Part of Cancer clinical trials.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have HER2-positive breast cancer (confirmed by a special test).
- Your cancer has not spread to other parts of the body (stage M0).
- You have not had any prior treatment for this breast cancer (like chemotherapy or surgery).
- Your heart function is good, and you do not have serious heart conditions or uncontrolled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how your cancer responds, aiming to give you the best possible outcome.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This study tests two ways to treat HER2-positive breast cancer before surgery: one uses a single drug (SHR-A1811), and the other uses that drug followed by a combination (THPy). The goal is to see which approach works better at shrinking tumors before surgery.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.